Latest Headlines

1. Nxera Joins OpenFold AI Research Consortium Alongside Leading Global Pharmaceutical And AI Companies To Accelerate AI-enabled Drug Discovery 6/10/2026

   Nxera Pharma Co., Ltd. (“Nxera” or the “Company”) announces that it has joined OpenFold, a non-profit AI research consortium that promotes the development of open-source AI software tools for biology and drug discovery.

2. XtalPi Announces Strategic Partnership With A Leading Biopharma To Develop Oral Small Molecule Therapeutics For A GPCR Target 6/10/2026
3. US FDA Grants Orphan Drug And Rare Pediatric Disease Designations To GEn1E Lifesciences' Dual Signal Modulator For The Treatment Of Duchenne Muscular Dystrophy 6/10/2026

   GEn1E Lifesciences Inc., a Phase 2 clinical-stage biotechnology company advancing AI-driven precision medicines for immunology, inflammation, and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted both Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) to GEn-1123 for the treatment of Duchenne Muscular Dystrophy (DMD).

4. Perpetual Medicines And Third Rock Ventures Deliver A Development Candidate In Under 18 Months Via Computational Physics And AI-Driven Platform 6/9/2026

   Perpetual Medicines, a biotechnology company pioneering the integration of computational physics and artificial intelligence for complex drug discovery, today announced the successful delivery of a development candidate in collaboration with Third Rock Ventures.

5. OpenFold Consortium Adds Eleven New Members As Momentum Builds For Open AI Infrastructure In Biology And Drug Discovery 6/9/2026

   OpenFold Consortium, an open science initiative advancing open-source AI tools for biology and drug discovery, announced today that eleven new members have joined the consortium including Absci, Adaptive Biotechnologies, Benchling, Chemical Computing Group, Daiichi Sankyo, Flagship Pioneering, Kiin Bio, Nanome, Nxera, Pledge Tx, and Superluminal.

6. Owkin To Build AI Agents As Part Of A Multi-Year K Pro Collaboration With Sanofi 6/5/2026

   Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist.

7. DaltonTx Launches Its Drug Discovery Platform, Dalton, And Announces Sygnature Discovery Collaboration 6/4/2026

   DaltonTx, the intelligence backbone for modern drug discovery: connecting AI, human expertise and experimental data, today announced the launch of Dalton, its drug discovery platform.

8. Chai Discovery Announces License Agreement With Pfizer To Accelerate Drug Discovery With AI 6/4/2026

   Chai Discovery, the company engineering AI models to discover new molecules, today announced a license agreement with leading biopharmaceutical company Pfizer.

9. Terremoto Biosciences Granted FDA Fast Track Designation For TER-2013, An AKT1-Selective Small Molecule Inhibitor For Breast Cancer 6/3/2026

   Terremoto Biosciences, a biotechnology company developing highly targeted, small molecule medicines, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation for TER-2013, the Company’s lead AKT1-selective inhibitor, in patients with locally advanced, unresectable or metastatic HR+/HER2- breast cancer harboring one or more AKT/PI3K/PTEN alterations following progression on at least one endocrine-based therapy and CDK4/6 inhibitor for advanced disease.

10. Ingenix Raises €13M From Sofinnova Partners-Led Syndicate To Scale Modality Fusion, A Novel Architecture For Drug Development 6/3/2026

    Ingenix, the AI and biology company built around a single question - "What would it take for AI to truly understand biology?" - has today announced a €13m seed-extension funding round led by Sofinnova Partners, with participation from Inovo VC and OTB VC.